These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 3526525)
1. [Comments on the therapeutic approach in myeloma]. Paule B; Médicis P; Clerc D; Ellrodt A; Bisson M; Massias P Rev Rhum Mal Osteoartic; 1986 Apr; 53(4):269-75. PubMed ID: 3526525 [No Abstract] [Full Text] [Related]
2. [Hemocytological classification, clinical staging and polychemotherapy of multiple myeloma]. István L; Karl W; Michael H; Günter A; Kelényi G; Várbíró M; Dieter R Orv Hetil; 1983 Feb; 124(6):313-9. PubMed ID: 6835675 [No Abstract] [Full Text] [Related]
3. [Reclassification of multiple myeloma and calculation of the myelomatous mass as prognostic and therapeutic indications]. Ricci C; Coscia GC; Uberti M; Discalzi G; Racca P Recenti Prog Med; 1982 Apr; 72(4):482-99. PubMed ID: 7146598 [No Abstract] [Full Text] [Related]
4. Multiple myeloma: a therapeutic enigma. Hoogstraten B Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
6. Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma. Bains MA; Pardoe LE; Rudin CE Br J Haematol; 2007 Jan; 136(2):179. PubMed ID: 17062009 [No Abstract] [Full Text] [Related]
7. Multiple myeloma: a tailored therapy for elderly patients. Pileri A; Palumbo A; Boccadoro M Hematol Oncol; 1993; 11 Suppl 1():67-72. PubMed ID: 8486344 [No Abstract] [Full Text] [Related]
8. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation. Richardson P Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847 [No Abstract] [Full Text] [Related]
9. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
17. Biology and therapy of multiple myeloma in 1996. Barlogie B; Jagannath S; Epstein J; Munshi N; Siegel D; Desikan KR; Feinman R; Hsu PL; von Bremen K; Tricot G Semin Hematol; 1997 Jan; 34(1 Suppl 1):67-72. PubMed ID: 9122748 [TBL] [Abstract][Full Text] [Related]
18. Prediction of therapeutic response in multiple myeloma by means of bone marrow cytology examination. Rapazzini P; Bettini R; Carcano L Haematologica; 1984; 69(5):640-1. PubMed ID: 6437939 [No Abstract] [Full Text] [Related]
19. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic progress--review XII. Treatment of multiple myeloma. Oakley JE; Franklin IM J Clin Hosp Pharm; 1984 Mar; 9(1):15-20. PubMed ID: 6371060 [No Abstract] [Full Text] [Related] [Next] [New Search]